ViewRay, Inc. designs, manufactures, and markets the MRIdian radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. MRIdian employs MRI-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. The Company believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients.
Type
Public
HQ
Oakwood Village, US
Founded
2004
Size (employees)
106 (est)
ViewRay was founded in 2004 and is headquartered in Oakwood Village, US
Report incorrect company information

Key People/Management at ViewRay

Chris Raanes

Chris Raanes

President and CEO
Gopinath Kuduvalli

Gopinath Kuduvalli

Vice President of Engineering
Stephen Strunk

Stephen Strunk

Vice President of Manufacturing

ViewRay Office Locations

ViewRay has offices in Cleveland, Mountain View and Oakwood Village
Oakwood Village, US (HQ)
2 Thermo Fisher Way
Cleveland, US
2 Thermo Fisher Way
Mountain View, US
800 West El Camino Real
Mountain View, US
815 E Middlefield Rd
Show all (4)
Report incorrect company information

ViewRay Financials and Metrics

ViewRay Financials

ViewRay's revenue was reported to be $34.04 m in FY, 2017
USD

Revenue (Q1, 2018)

26.2 m

Gross profit (Q1, 2018)

5.6 m

Gross profit margin (Q1, 2018), %

21.3%

EBIT (Q1, 2018)

(11.3 m)

Market capitalization (25-May-2018)

524.8 m

Closing share price (25-May-2018)

7

Cash (31-Mar-2018)

78.9 m

EV

490.5 m
ViewRay's current market capitalization is $524.8 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

6.4 m10.4 m22.2 m34 m

Revenue growth, %

62%114%

Cost of goods sold

9.2 m14.5 m25.9 m27.7 m

Gross profit

(2.8 m)(4.2 m)(3.6 m)6.3 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

5.3 m5.5 m299 k357 k1.2 m698 k26.2 m

Cost of goods sold

6.1 m6.5 m863 k1.2 m1 m826 k20.6 m

Gross profit

(775 k)(1.1 m)(564 k)(826 k)185 k(128 k)5.6 m

Gross profit Margin, %

(15%)(20%)(189%)(231%)15%(18%)21%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

11.1 m20.7 m14.2 m57.4 m

Accounts Receivable

904 k830 k4.2 m20.3 m

Inventories

8.2 m8.1 m8.1 m19.4 m

Current Assets

28.4 m43.6 m35.9 m122.7 m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

32.1 m5.7 m9.4 m14.6 m49.3 m53.9 m78.9 m

Accounts Receivable

1 k830 k1.7 m300 k3.3 m1.8 m26.2 m

Inventories

2.5 k2.5 k2.5 k9.6 m11.9 m11.2 m10.4 m10.2 m15.4 m30.4 m

Current Assets

52.3 m26.5 m34.5 m42.6 m78.2 m92.9 m154 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(33.8 m)(45 m)(50.6 m)(72.2 m)

Depreciation and Amortization

1 m1.3 m1.7 m2.2 m

Inventories

(703 k)(1.7 m)(12.3 m)

Accounts Payable

(2.1 m)381 k6.3 m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(1.6 k)(30.9 m)(14.1 m)(28 m)(4.8 m)

Depreciation and Amortization

913 k658 k

Inventories

2.5 k(2.4 m)11.9 m11.2 m10.4 m10.2 m(12 m)

Accounts Payable

80 (6 m)6.7 m6 m1.7 m5.6 m2.1 m
USDY, 2018

EV/EBIT

-43.4 x

EV/CFO

-13.1 x

Financial Leverage

2.9 x
Show all financial metrics

ViewRay Operating Metrics

ViewRay's Backlog was reported to be 133.2m in FY, 2016.
FY, 2016

Backlog

133.20 m

Patents (US)

19

Patents (foreign)

31

Patents Pending

108
Show all operating metrics
Report incorrect company information

ViewRay News and Updates

Report incorrect company information